Allergic conjunctivitis is an eye inflammation that involves the infiltration of immune cells into the conjunctiva via cell surfaceadhesion receptors, such as integrin α 4 β 1 . These receptors interact with adhesion molecules expressed on the conjunctival endothelium and may be a target to treat this disease. We synthesized DS-70, a novel α/β-peptidomimetic α 4 integrin antagonist, to prevent the conjunctival infiltration of immune cells and clinical symptoms in a model of allergic conjunctivitis.
Introduction
Allergic conjunctivitis includes a variety of ocular inflammatory diseases that are mainly caused by type 1 hypersensitivity reactions related to the preferential generation of IgE antibodies . The early phase reaction occurs when allergens recognize IgE antibodies bound to the high-affinity receptor for the Fc region of IgE on conjunctival mast cells. This event triggers mast cell degranulation, histamine release and the generation of prostaglandins, leukotrienes, cytokines and chemokines, causing ocular itching and hyperaemia. Additional symptoms include swelling of the surrounding eyelids, chemosis and tearing. The early phase reaction leads to a late phase after 6-12 h that is sustained by T-cell-dependent processes through the production of cytokines and chemokines that mediate the recruitment and conjunctival infiltration of eosinophils and other immune cells (Choi and Bielory, 2008) . This latter event requires the interaction between leukocyte surface-adhesion receptors, such as integrins and selectins, and adhesion molecules expressed on the conjunctival endothelium, such as intercellular adhesion molecule-1 (ICAM-1) (Oh et al., 1999) and vascular cell adhesion molecule-1 (VCAM-1) (Baiula et al., 2012) . Increased levels of cell adhesion molecules on the microvasculature and factors that regulate these molecules may perpetuate inflammation in allergic conjunctivitis (Okada et al., 2005) .
Integrin α 4 associates with a β 1 or β 7 subunit on leukocytes to form the integrin heterodimers α 4 β 1 and α 4 β 7 that mediate cell adhesion to VCAM-1 and fibronectin (FN) and behave as both adhesion and signalling molecules (Kummer and Ginsberg, 2006) . Integrin α 4 β 7 is predominantly expressed in a subpopulation of CD4(+) CD45RA(+) T-cells, which have been shown to preferentially home to the gut through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) (Wright et al., 2002) .
Integrin α 4 β 1 is expressed in mast cells, which contributes to the recruitment and influences migration and functional responses (Hallgren and Gurish, 2011) . This integrin is also expressed on eosinophils (Barthel et al., 2008) , mediating their activation and infiltration in inflamed tissues (Ahmadzai et al., 2015) , including the conjunctiva (Abu el-Asrar et al., 1997; Baiula et al., 2012) . Studies using monoclonal antibodies have confirmed that α 4 integrin contributes to eosinophil recruitment in allergic inflammatory diseases (Ebihara et al., 1999; Fukushima et al., 2006) . Based on these findings, the blockade of α 4 β 1 integrin may represent a useful therapeutic strategy to treat allergic eye diseases. Current therapies for allergic conjunctivitis mainly include antihistamines and mast cell-stabilizing agents that only alleviate clinical symptoms, or glucocorticoids whose use is limited by adverse effects (Abelson et al., 2015) . Therefore, safer and more effective drugs are required to treat allergic eye diseases .
Low MW antagonists of integrin α 4 decrease airway inflammation in animal models of allergic asthma (Cortijo et al., 2006; Kenyon et al., 2009) . Furthermore, topical administration of an α 4 integrin antagonist improves ocular surface inflammation in a murine model of dry eye (Ecoiffier et al., 2008) and in established ocular surface disease associated with Sjögren's syndrome (Contreras-Ruiz et al., 2016). The efficacy of α 4 integrin antagonists in treating allergic conjunctivitis has been poorly explored. Drugs are frequently administered topically in the conjunctival fornix to treat this pathology , and low MW α 4 antagonists are suitable for administration via this route.
In the present study, we report the synthesis of two novel hybrid α/β-peptides and their pharmacological characterization as potent and selective α 4 integrin antagonists. Recently, we described a series of α 4 β 1 integrin antagonists based on a β-amino acid central core, an α 4 integrin-targeting diphenylurea moiety and a moiety carrying a β1-targeting acidic functionality at the C terminus flanked by an aromatic substituent (Dattoli et al., 2014; De Marco et al., 2015) . The β-amino acids were chosen to increase peptide stability and for the conformational control exerted on the overall structure . Following these early investigations, we synthesized the novel hybrid α/β-peptidomimetics DS-70 and DS-23, which include a (D)-configured β 2 -proline (the D configuration of this β-residue corresponds to the S absolute stereochemistry). Similar to the reference compound BIO1211, DS-70 showed a linear sequence completed by o-methylphenylureaphenylacetyl (MPUPA) and a simple glycine. In contrast, DS-23 represented the partially retro analogue of DS-70, since the β-amino acid central core was connected to 1-(4-(aminomethyl)phenyl)-3-(O-methyl)urea (AMPUMP) and to the diacid equivalent of glycine ( Figure 1 ). Indeed, retro-peptide sequences showed higher efficacy against α 4 β 1 integrins compared to the corresponding normal sequences in our previous studies (Dattoli et al., 2014; De Marco et al., 2015) .
Pharmacological characterization of these novel compounds was performed in vitro using a scintillation proximity procedure to measure their affinity for α 4 β 1 integrin, and their effects on cell adhesion mediated by this integrin were also evaluated. DS-70 was the most potent compound and was assayed in VCAM-1-mediated degranulation of HMC 1.1 cells, a human mast cell line, and EoL-1 cells, a human eosinophilic leukaemia cell line, both of which express α 4 β 1 integrin (Sperr et al., 1992; Jung et al., 1994) . Furthermore, DS-70 antagonized VCAM-1-mediated phosphorylation of ERK 1/2 in Jurkat E6.1 cells. Finally, the effects of topical treatment with DS-70 on a guinea pig model of allergic conjunctivitis were evaluated. DS-70 dose-dependently reduced clinical aspects of allergic conjunctivitis, conjunctival mast cell and eosinophil infiltration, α 4 integrin expression and levels of mRNAs for IL-1β, IL-8 (CXCL8), CCL5 and CCL11. Protein levels of these latter chemokines were also measured. To the best of our knowledge, this report is the first to describe a low MW compound that acts as an effective antagonist of α 4 integrin, following direct administration in the conjunctival fornix in a model of allergic conjunctivitis. 1100 series apparatus, equipped with a RP column Phenomenex (Torrance, CA, USA) No 00D-4439-Y0 Gemini 3 μm C18 110 Å, LC column 100 × 3.0 mm; diode-array detection was set at 210 nm. Mobile phase description: gradient from 0.1% formic acid (0.1 mL·100 mL À1 ) in H 2 O/acetonitrile 
Synthesis of DS-70
Fmoc (fluorenylmethoxycarbonyl)-Gly-Wang preloaded resin (Sigma-Aldrich, Milan, Italy; 0.5 g, amino acid load = 0.4-0.8 mmol·g À1 according to the manufacturer) was placed into a syringe equipped with a frit.
Fmoc deprotection. The Fmoc protecting group was cleaved in 2 min by treatment with 20% piperidine in dimethylformamide (DMF) (5 mL) while bubbling nitrogen, under microwave irradiation (irradiation power = 40 W, internal reaction temperature = 45°C; see above). The resin was filtered and washed with CH 3 OH (5 mL), DMF (5 mL) and CH 2 Cl 2 (5 mL) in sequence. The cleavage procedure and washes were repeated twice as described above. The deprotection was qualitatively assessed by a positive Kaiser test.
Coupling. The acid-partner (0.9 mmol) was dissolved in DMF (6 mL) at room temperature, in the presence of hydroxybenzotriazole (HOBt) (0.9 mmol) and N,N 0 -dicyclohexylcarbodiimide (DCC) (0.9 mmol). After stirring for 5 min, the mixture was added to the resin pre-swollen in CH 2 Cl 2 (5 mL). The suspension was mechanically shaken for 10 min under microwave irradiation. Then, the resin was filtered and washed three times with the same solvents as described in the paragraph above. The coupling was assessed by the Kaiser test. The repetitive deprotection and Figure 1 coupling steps were carried out according to the same protocols and workup procedures ( Figure S1A ).
Peptide cleavage. The peptidyl-resin obtained according to the previous protocol was pre-swollen in CH 2 Cl 2 (3 mL) and treated with a 90:5:5 mixture of TFA/H 2 O/ triisopropylsilylether (10 mL), plus phenol (50 mg), and the mixture has mechanically shaken at room temperature for 2 h. Subsequently, the cocktail was filtered to recover the peptide, and the unloaded resin was washed with 20% TFA in diethyl ether (5 mL), CH 2 Cl 2 (5 mL) and CH 3 OH (5 mL) in sequence. The filtrates were collected; the volatiles were removed with a moderate nitrogen flow at room temperature. The solid residue was suspended in icecold diethyl ether to favour peptide precipitation. The crude peptide was triturated and collected by centrifugation at 2000× g for 10 min.
The peptide was isolated (78% yield) by semipreparative RP-HPLC, and purity was assessed by analytical RP-HPLC (98% C23H26N4O5: 439.19; found: 439.30. BIO1211 (N-[[4-[[[(2-methylphenyl) (Figure 1 ) was prepared adopting the above-described procedure. 
Synthesis of DS-23
Boc (tert-butyloxycarbonyl)-β-Pro (1.0 mmol) was dissolved in 4:1 CH 2 Cl 2 /(5 mL) in the presence of HOBt (1.1 mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexauorophosphate (HBTU; 1.1 mmol), and the mixture was stirred at room temperature under an inert atmosphere for 5 min. Thereafter, AMPUMP-TFA salt (1.1 mmol) was added at room temperature while stirring, followed by N, N-diisopropylethylamine (DIPEA; 2.2 mmol). The mixture was stirred for 10 min under microwave irradiation (see above). The mixture was diluted with CH 2 Cl 2 (40 mL) and washed with 0.5 M HCl (5 mL) and with saturated solution of NaHCO 3 (5 mL). The organic layer was dried over Na 2 SO 4 , and solvent was removed at reduced pressure. The protected intermediate was isolated (75%) by flash chromatography over silica-gel (eluent: 100% ethyl acetate).
Subsequently, the Boc group was removed by treatment with 25% TFA in CH 2 Cl 2 (10 mL). The mixture was subjected to moderate nitrogen flow at room temperature until a solid residue was obtained.
The resulting TFA salt was utilized without purification and coupled with 3-(benzyloxy)-3-oxopropanoic acid under the same conditions as described above, following the same work up, including the isolation of the intermediate.
The benzyl ester was removed by treatment with H2 palladium on carbon in ethanol for 4 h ( Figure S1B ) at room temperature. The mixture was filtered over Celite® (SigmaAldrich), and the filter was washed with ethanol (10 mL). After evaporation of the collected ethanol layers at reduced pressure, the final purification of the residue was accomplished with semi preparative RP-HPLC, and purity was determined by analytical RP-HPLC (97%; see the General procedure for the synthesis of peptidomimetics 
Animals
All animal care and experimental protocols complied with the EU Directive 2010/63 and the D. Lgs. 116/92 of the Italian legislation in effect at the time of the study (June and July, 2012) . The Scientific Ethics Committee on Animal Experimentation of the University of Bologna approved the experimental protocol adopted (protocol n. 31331-X/10; July 22, 2011). This study followed the editorial on experimental design and analysis in pharmacology (Curtis et al., 2018) . Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . Fifty male Hartley albino guinea pigs (250-300 g, 6-to 8-week-old) obtained from Charles River Laboratories Italia (Calco, Italy) were used. Animals were housed in groups of five to six in a controlled environment at 22-24°C and humidity 60-62%, with a 12 h light/dark cycle and access to food (Teklad Global Guinea Pig Diet 2040) and tap water ad libitum. All efforts were made to minimize animal suffering. The cages contained soft bedding and environmental enrichment for welfare purposes, and the animals were allowed to acclimatise to this environment for 7-9 days after arrival in the unit before use.
Ovalbumin sensitization
Animals were sensitized to chicken-derived ovalbumin using aluminium hydroxide as an adjuvant to promote an IgEmediated conjunctival allergic response (Groneberg et al., 2003) . Guinea pigs were randomly divided into eight experimental groups of five animals per group. Group sizes were based on our earlier studies with the ovalbumin-challenge model showing a significant and reproducible conjunctival inflammation with eosinophil infiltration (Qasem et al., 2008; Baiula et al., 2011) . Five groups were sensitized on days 1, 7 and 14 by an i.p. injection of 200 μg of ovalbumin with 40 mg of aluminium hydroxide suspended in 200 μL of saline, as previously reported (Qasem et al., 2008) , and three groups received an i.p. injection of 200 μL of saline (control). On day 21, sensitized guinea pigs and one control group received 30 μL of saline containing 3 mg of ovalbumin in the conjunctival fornix of both eyes; 30 and 10 min before ovalbumin challenge, three groups of sensitized animals received 30 μL of a vehicle containing 0.01, 0.05 and 0.1%, (w/v) of DS-70, respectively, in the conjunctival fornix of both eyes and gently closing the eyelid to prolong the drug residence time in the conjunctiva (Awwad et al., 2017 ). Another group of ovalbumin-sensitized guinea pigs and a control group received 30 μL of vehicle per eye 30 and 10 min before ovalbumin challenge. The second control group received 30 μL of 0.1 g·100 mL À1 DS-70 in both eyes 30 and 10 min before topical saline administration. The last control group received dexamethasone (30 μL of 0.1 g·100 mL À1 ; 0.1% ), 30 and 10 min before topical saline administration. Finally, an ovalbumin-sensitized guinea pig group received 30 μL of 0.1% dexamethasone in both eyes 30 and 10 min before ovalbumin challenge. Clinical conjunctival symptoms were rated in both eyes using the following scale: 0, no symptoms; 1, slight conjunctival redness with or without tears; 2, mild conjunctival redness with or without tears and mild chemosis; 3, mild conjunctival redness with or without tears and moderate chemosis; 4, severe conjunctival redness with tears and partial lid eversion; 5, severe conjunctival redness with tears and lids more than half closed. Photographs of both eyes were taken to evaluate the clinical score 30 min before ocular treatments and 1, 2, 4, 6 and 24 h after ovalbumin administration. The animals were killed 24 h after ovalbumin challenge. Guinea pigs were sedated, prior to ovalbumin challenge, with a mixture of Ketalar® and Rompun® (32 mg·kg Tarsal conjunctiva were carefully excised from both eyes and divided into separate samples for subsequent investigations. One sample was fixed with a 10% buffered paraformaldehyde solution and embedded in paraffin. Slices (6 μm thick) were stained to determine the number of mast cells and eosinophils and to perform immunohistochemical (IHC) assays. Other samples were collected to quantify eosinophil peroxidase activity, cytokine and chemokine mRNA levels.
Conjunctival absorption of DS-70
To evaluate the conjunctival absorption of DS-70 in guinea pigs, this compound (30 μL of 0.1 g·100 mL À1 ) was administered in the right eye, whereas the contralateral eye was treated with the vehicle used to dissolve DS-70. Ttwo treatments were given, 30 min apart. Guinea pigs (five per group) were killed with pentobarbital (100 mg·kg À1 i.p.), 1 h or 6 h after the first treatment. Tarsal conjunctiva was collected, weighed and processed as described (Iyer et al., 2015) to extract DS-70. Internal standard was levocabastine hydrochloride (0.5 mg·mL À1 ). DS-70 was quantified using a standard curve (84 μg·mL À1 -27 ng·mL À1 ). Detection of DS-70 and levocabastine was carried out as previously described in the paragraph 'Synthesis of DS-70'.
Validity of animal species and model selected for study
Allergic conjunctivitis is a localized pathological condition that is observed as the only or dominant presentation of an allergic sensitization when an allergen irritates conjunctiva or is associated with rhinitis. Ocular symptoms, which are estimated to be present in more than 75% of allergic patients, include itching, tearing, redness and swelling, but no pain. Signs and symptoms of allergic conjunctivitis involve a complex series of immunological mechanisms initiated by the sensitization to a novel allergen. Upon re-exposure, the antigen is recognized by allergen-specific IgE receptors located on conjunctival mast cells, leading to their activation and degranulation . We have adopted a guinea pig model of allergen exposure and challenge (Qasem et al., 2008; that is similar to models used in the clinic. Conjunctival manifestations of ocular allergy are caused by immune cell activation and the release of allergic mediators on the ocular surface that have been detected in animal models and in patients (Groneberg et al., 2003) . Several inflammatory intermediates, such as proteins, cytokines and chemokines, have been proposed as potential biomarkers of allergic conjunctivitis in patients (Irkec and Bozkurt, 2012) and have been assayed in animal models . In contrast to the large amount of experimental studies on allergic asthma, few experimental studies have used models of allergic eye diseases. Guinea pigs are among the major laboratory animal species employed for the assessment of ocular allergies, as they have proved to be a valid model to assess the anti-allergic effects of established and newly developed compounds, which are mainly administered directly into the conjunctival sac (Groneberg et al., 2003) .
Cell culture
All cell lines were purchased from the ATCC (Rockville, MD, USA) except as otherwise specified. Cell culture medium of each cell line is described in detail in Table S2. HEL cells respectively. This treatment induced cell differentiation and increased expression of α 5 β 1 and α M β 2 integrins on the cell surface (Baiula et al., 2016) . Integrin expression in the cell lines noted above has been previously described (Erle et al., 1994; Baiula et al., 2016) and is summarized in Table S2 .
Scintillation proximity assay
We modified a scintillation proximity assay (SPA) previously developed in our laboratory (Qasem et al., 2008) to detect competitive binding of the tested compound to soluble [ 125 I]-human FN (MW approximately 440 kDa) bound to an antibody-captured integrin α4β1 complex. α4β1 integrin was extracted from Jurkat E6.1 cells and purified by affinity chromatography, following a procedure to extract membrane proteins (Qasem et al., 2008) . The experiments were carried out in scintillation vials kept in the dark; an aliquot of cell eluate containing approximately 100 μg of α 4 β 1 integrin was added together with increasing concentrations of the tested compounds for 90 min at room temperature. Then, the rabbit anti-human α 4 integrin antibody was added for 1 h at 4°C. Thereafter, the beads coated with the anti-rabbit IgG antibody (400 ng) were added, and the mixture was incubated for 2 h at 4°C. Finally, we added [
125 I]-FN (10 5 counts per minute) to the vials that were then incubated for 24 h at room temperature on a shaker. Non-specific binding was determined in the presence of the specific α 4 β 1 integrin antagonist BIO1211 (100 mM). Bead-associated radioactivity was measured using a LS 6500 multipurpose scintillation counter (Beckham Coulter, Fullerton, CA, USA). 
Cell adhesion assays
The assays were performed as previously described (Tolomelli et al., 2015; Baiula et al., 2016 ). Alternatively, Jurkat E6.1 cell adhesion assays were performed in plates coated with ICAM-1 (2 μg·mL À1 ). A saturation curve for each ligand was plotted to establish the best signal-to-noise ratio. Non-specific hydrophobic binding sites were blocked, for 30 min at 37°C, by incubation with BSA (1 g·100 mL À1 ) dissolved in HBSS.
The number of adherent cells was calculated by comparison with a standard curve prepared in the same plate using known concentrations of labelled cells. The effect of antagonists was evaluated by the reduction in adherent cells in comparison to the controls. Adhesion assays were also carried out in the presence of an anti-human α 4 integrin antibody (5 μg·mL À1 ). Experiments were carried out in quadruplicate and repeated at least five times.
Western blot analysis
Jurkat E6.1, EoL-1 and HMC 1.1 cells were cultured for 16/18 h in medium containing a reduced amount of FBS (1 g·100 mL À1 ). Then, 3 × 10 6 cells were pre-incubated with different concentrations of DS-70 for 60 min and then seeded for 1 h in VCAM-1-(2 μg·mL À1 ) coated plates and lysed on ice using a mammalian protein extraction reagent (M-PER; Pierce, Rockford, IL, USA) in the presence of a phosphatase inhibitor cocktail. Protein extracts were quantified using a BCA protein assay kit (Pierce, Rockford, IL, USA), heated for 5 min at 95°C, and equal amounts of the samples were separated by 12% SDS-PAGE gel, transferred onto nitrocellulose membranes and immunoblotted with the indicated antibodies. Incubations with anti-phospho-ERK 1/2 (1:1000) (Cell Signaling Technology, Danvers, MA, USA) or anti-total ERK1/2 antibodies (1:2500) (Cell Signaling Technology) took place overnight at 4°C in the presence of BSA (5 g·100 mL À1 )
in Tris buffered-saline containing Tween-20 (0.1 g·100 mL À1 ).
After washing, anti-rabbit HRP-conjugated secondary antibodies (Santa Cruz Biotechnology, Dallas, TX, USA) were added to membranes for 1.5 h at room temperature. Protocols for image acquisition and analysis have been previously described .
HUTS-21 monoclonal antibody binding
Flow cytometry analysis was carried out in accordance to protocols previously described (Baiula et al., 2016 
Flow cytometry
For the detection of cell surface α 4 integrin, cells were collected from culture plates, washed two times with PBS and incubated with a FITC-labelled anti-α 4 antibody (FITC Mouse anti-human CD49d, Becton Dickinson Italia) (5 μL per sample) for 45 min at room temperature. Flow cytometry was performed using a Guava EasyCyte Flow Cytometer (Merck).
To detect any apoptosis and/or necrosis in Jurkat E6.1, EoL-1 and HMC 1.1 cell lines exposed to DS-70, 75 000 cells per well were incubated with the compound (10 À4 M) for 6 h at 37°C. A mixture 1:1 of complete medium/Guava Nexin Reagent (Merck) was added to cells, following the manufacturer's instructions for staining. Viable cells [annexin V-PE and 7-aminoactinomycin D (7-AAD) negative], early apoptotic cells (annexin V-PE positive and 7-AAD negative), and late stage apoptosis or necrotic cells (annexin V-PE and 7-AAD positive) were separately counted. At least 10.000 cells per sample were acquired.
Cell degranulation assays
Degranulation assays were carried out in HMC 1.1 and EoL-1 cells. β-Hexosaminidase, a marker of mast cell degranulation, was quantitated to measure HMC 1.1 degranulation as these cells exhibit many characteristics of tissue mast cells (Sundström et al., 2003) . Each experiment was carried out in triplicate and repeated at least five times. Values are expressed as percentage of degranulation and derived from the following equation: (experimental β-hexosaminidase release À vehicle β-hexosaminidase release)/(Triton X-100 β-hexosaminidase release À vehicle control β-hexosaminidase release) × 100.
The o-phenylenediamine method previously described by us (Qasem et al., 2008) was used to measure eosinophil peroxidase release. Measurement of absorbance was performed at 490 nm using a Victor 2 multilabel counter (PerkinElmer, Milan, Italy). Each experiment was carried out in triplicate and repeated at least five times.
Histological and immunofluorescent detection of mast cells and eosinophils
Degranulated mast cells were evaluated in photographs of three random sections (6 μm thick) per eye obtained from tarsal conjunctiva specimens, stained in May-Grünwald-Giemsa solution (Sigma-Aldrich) for 60 min at room temperature and detected with a light microscope Nikon Eclipse E800 (Nikon Instruments S.p.a., Florence, Italy) (400× magnification). Histological sections of tarsal conjunctiva (6 μm thick) were processed to determine eosinophil infiltration using a classical Luna's protocol (Baiula et al., 2011) . The sections were immersed in haematoxylin-Biebrich scarlet solution for 5 min, dipped (~8×) in 1% acid alcohol (Sigma-Aldrich) and rinsed in water. Sections were then dipped (~5×) in lithium carbonate (0.5 g·100 mL À1 ) until turned blue and washed in running tap water. Pictures were taken of three random sections per eye, and eosinophils were detected under light microscopy (500× magnification). Eosinophils or degranulated mast cells were counted and expressed as number of cells·mm
À2
. For co-labelling experiments, conjunctival sections were incubated with blocking solution containing BSA (1 g·100 mL À1 ), glycine (22.5 mg·mL À1 ) and Tween20 
Eosinophil peroxidase assay
In separate conjunctival specimens, eosinophil peroxidase activity was assayed as previously described (Qasem et al., 2008) . The tissues were homogenized with 50 mmol·L
À1
Tris-HCl buffer (pH 8.0) on ice, and after adding 50 mmol·L
Tris-HCl buffer and 0.1% Triton X-100, homogenates were placed in an ice bath for 1 h. Then, the substrate solution (50 mmol·L À1 Tris-HCl buffer containing 0.1% Triton X-100, 1 mmol·L À1 o-phenylenediamine, 3 mmol·L À1 KBr and 0.5 mmol·L À1 hydrogen peroxide) was added to samples and incubated at 37°C for 10 min. The reaction was stopped with 4 mol·L À1 H 2 SO 4 . Absorbance was measured using a spectrophotometer at 490 nm. The oxidation of o-phenylenediamine, in the presence of hydrogen peroxide and KBr, was used to measure the peroxidase-mediated catabolism of hydrogen peroxide. One unit corresponds to 1 mmol of hydrogen peroxide decomposed in 10 min. Results are expressed as mU of enzyme·mg À1 wet tissue.
IHC analysis
Slices prepared from tarsal conjunctiva specimens were subjected to deparaffination in xylene and rehydration in serial dilutions of ethanol. Antigen retrieval step was done in citrate buffer (pH 6.0) for 20 min. Sections were washed three times in Tris-buffered saline containing Tween-20 (0.025 g·100 mL À1 ) (Sigma-Aldrich).
Complete staining was achieved by means of a specific HRP/DAB detection kit (Abcam). The reagents constitute a labelled streptavidin-biotin immuno-enzymic antigen detection system. Briefly, after slice incubation with a protein blocking buffer (Abcam), sections were incubated overnight at 4°C with primary antibodies (100 μL per sample) for CCL11 or CCL5 (Abcam; diluted 1:250) or α 4 integrin (Becton Dickinson; diluted 1:500). Slices were incubated with biotinylated goat anti-rabbit IgG to detect CCL5 and CCL11 or goat anti-mouse IgG1 to detect α 4 integrin for 10 min at room temperature and were developed according to the manufacturer's instructions. Isotype negative controls were performed with an isotype-matched antibody. A mouse IgG1 (Abcam) was the negative control for integrin α 4 and a rabbit IgG polyclonal antibody (Abcam) the negative control for CCL5 and CCL11. Anti-human antibodies for CCL5, CCL11 and α 4 integrin were employed as their protein sequences are almost completely conserved between human and guinea pig and other researchers have previously employed those antibodies in guinea pig tissues successfully.
Relevant photomicrographs were taken with a 20× objective. The analysis was done on the basis of a validated semiquantitative scoring method (Walker, 2006) . The resulting percentage of tissue showing positive staining is expressed as IHC score that was assigned by two blinded researchers to quantitate IHC-positively stained cells and areas, according to five categories: 0, no staining; 1, <25% staining; 2, 25-50% staining; 3, 50-75% staining; and 4, >75% staining.
Real time RT-PCR
Total RNA from tarsal conjunctiva specimens was extracted employing TRI-Reagent. RNase-free DNase treatment was performed for each sample, and 1 μg of RNA was converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies Italia, Milan, Italy), according to the manufacturer's instructions. GoTaq® qPCR Master Mix was chosen to perform the reaction as follow: denaturation at 95°C for 10 min, followed by 40 cycles of 95°C denaturation (20 s) and 58°C annealing (1 min). No-template controls and DNA melting curve analysis were used as controls. For data analysis, the threshold cycle (Ct) values were normalized both on the basis of GAPDH content and on the values derived from non-immunized guinea pigs. GAPDH, IL-8, IL-1β, CCL11 and CCL5 primer sequences are listed in Table S1 and was first reported in .
Data and statistical analysis
All in vitro data are the means ± SD, of at least five independent experiments, whereas for the in vivo experiments, five animals per group were included and both eyes were analysed (n = 10). Statistical comparisons were performed using oneway ANOVA and post hoc Newman-Keuls test. The scores assigned to the conjunctival symptoms were nonparametrically analysed using the Friedman test, followed by Dunn's post hoc comparison. Significant differences among IHC scores were assessed by the Kruskal-Wallis test followed by Dunn's post hoc comparison. Data analysis and IC 50 values referring to experiments not mentioned above were obtained using GraphPad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). The data deriving from HUTS-21 binding antibody were fitted using the sigmoidal dose-response equation using GraphPad Prism. P < 0.05 was considered significant.
Data related to the clinical conjunctival symptoms are presented as scatter plot. As regards the data presented as bar charts, scatter plot analysis did not reveal any unusual or interesting aspect not obvious from the bar chart (George et al., 2017) . The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) .
Blinding procedures in experiments
Researchers involved in the experiments, data collectors, outcome adjudicators and data analysts who did not participate in the study were blinded to reduce the risk of bias. Personnel who did not perform the experiments prepared the compounds administered. 
Materials

Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2015 .
Results
Peptide synthesis, general procedure
The linear peptides BIO1211 and DS-70 were prepared by solid phase peptide synthesis on a Wang resin, using Fmoc-protected amino acids, under microwave irradiation conditions optimized by us . The removal of Fmoc group was performed by treatment with piperidine in DMF, under microwave irradiation for 2 min. Coupling between each residue was carried out with the activating agents DCC and HOBt in 4:1 CH 2 Cl 2 (dichloromethane)/DMF under microwave irradiation for 10 min. Peptide cleavage was accomplished by treatment of the peptidyl-resin with TFA in CH 2 Cl 2 and scavengers. The crude products were simply precipitated from ice-cold diethyl ether and collected in almost quantitative yield by centrifugation. On the other hand, the retro sequence DS-23 was prepared in solution. AMPUMP was coupled with Bocprotected β-Pro in solution under microwave irradiation, with the aid of HOBt/HBTU/DIPEA. Boc deprotection of the resulting dipeptide was done in TFA and was followed by coupling with 3-(benzyloxy)-3-oxopropanoic acid under the same conditions previously described. The resulting benzyl ester was deprotected by catalytic hydrogenation, giving DS-23 in good yield. Finally, all peptides were purified (96-98%) with semi-preparative RP-HPLC and identified by ESI-MS HPLC.
Binding affinity of α/β-peptides for human α 4 β 1 integrin as measured by SPA and inhibition of α 4 integrin-mediated cell adhesion
The binding of the reference compound BIO1211 and the novel hybrid α/β-peptides to α 4 β 1 integrin was measured using a SPA. [
125 I]-FN was the specific radioligand, and α 4 β 1 integrin was extracted from human Jurkat E6.1 cells (endogenous expression). Western blot analyses of the α 4 β 1 integrin extracted from cell lysates and purified by affinity chromatography confirmed that both α 4 and β 1 integrin subunits are present in the eluate employed in the assay ( Figure S2, panel A) .
[ 125 I]-FN binding was inhibited by the well-established α 4 β 1 integrin antagonist BIO1211 and by the novel hybrid α/β-peptides DS-70 and DS-23 in a concentration-dependent manner. As reported in Table 1 , the most effective ligands were DS-70 and BIO1211, which showed the lowest and superimposable IC 50 values.
Subsequently, we assayed the ability of hybrid α/β-peptides to inhibit adhesion of α 4 β 1 integrin-expressing Jurkat E6.1 cells to VCAM-1 or FN. Jurkat E6.1 cell adhesion to both adhesion molecules was inhibited (>95%) after treatment with a specific anti-α 4 antibody (data not shown). The reference compound BIO1211 and the hybrid α/β-peptides DS-70 and DS-23 blocked Jurkat E6.1 cell adhesion in the nanomolar range (Table 1) .
DS-70 was more effective than DS-23 as an antagonist of α 4 β 1 integrin and we therefore focused our research efforts on this compound. First, we assessed whether DS-70 inhibited the adhesion of the human mast cell line HMC 1.1 and of the human eosinophilic cell line EoL-1, both of which mainly express α 4 β 1 integrin, to VCAM-1 or FN. This compound showed IC 50 values similar to the values observed in Jurkat E6.1 cells ( Table 2 ).
The expression of α 4 integrin on the surface of Jurkat E6.1, EoL-1 and HMC 1.1 cell clones employed in this study was confirmed using a FITC-labelled anti α 4 antibody by flow cytometry. As reported in Figure S3 , the three cell lines express consistent levels of this integrin on their surface. All the other cell lines employed for cell adhesion assays, as shown in Figure S3 , do not express α 4 integrin. RPMI 8866 cells predominantly express the leukocyte integrin α 4 β 7 , and the adhesion molecule MAdCAM-1 predominantly measures α 4 β 7 -mediated cell adhesion (Erle et al., 1994) . DS-70 was approximately eightfold less potent in blocking cell adhesion mediated by α 4 β 7 integrin binding to MAdCAM-1 in RPMI 8866 cells (Table 2 ) compared to VCAM-1 and FN-mediated cell adhesion in EoL-1 or HMC 1.1 cells. Furthermore, DS-70 did not inhibit cell adhesion mediated by the leukocyte integrins α L β 2 and α M β 2 or by the Arg-Gly-Asp-binding integrins α 5 β 1 , α V β 3 , α V β 5 , α V β 6 and α IIb β 3 (Table 2 ). Taken together, these results confirm that DS-70 may behave as a competitive antagonist of cell adhesion molecules that preferentially bind to α 4 integrin.
In vitro enzymic stability of DS-70
The in vitro stability of DS-70 in mouse serum at 37°C was compared with BIO1211. As shown in Figure S4 , BIO1211 had an approximate half-life of 0.27 ± 0.07 h (mean ± SD; n = 5). DS-70 was more stable, and after 8 h, 21 ± 2% of its content in serum had degraded. These data support the hypothesis that the presence of the β-amino acid scaffold markedly increased the enzymic stability of this peptidomimetic.
Effects of DS-70 on VCAM-1-mediated ERK 1/2 phosphorylation
Intracellular signalling generated by the interaction of components of the extracellular matrix with integrin α 4 β 1 involves second messengers such as ERK1/2 that contribute to α 4 integrin-mediated cell functions (Abdala-Valencia et al., 2011). The addition of DS-70 alone to Jurkat E6.1 cells did not cause any significant increase in ERK 1/2 phosphorylation compared to vehicle-treated cells (data not shown). A significant increase in ERK 1/2 phosphorylation was detected 60 min after Jurkat E6.1 cells were exposed to VCAM-1-coated plates (2 μg·mL À1 ). Pre-incubation with
DS-70 (10
À10
-10 À4 M) for 60 min, produced a concentrationdependent decrease in VCAM-1-mediated ERK1/2 phosphorylation (Figure 2A,B) . DS-70 was also effective in reducing, in a concentration-related manner, ERK 1/2 phosphorylation induced by VCAM-1 in HMC 1.1 and EoL-1 cells ( Figure S5 ). (Margadant et al., 2011) . Conformational changes in integrin subunits may be monitored using conformation-specific antibodies that recognize a specific epitope that is exposed only in a defined structural conformation (Luque et al., 1996) . We used the PE-conjugated HUTS-21 mAb to determine whether the binding of DS-70 to α 4 β 1 integrin alters its conformation. This mAb recognizes a ligand-induced binding site epitope that is masked in the inactive integrin but is exposed upon agonist binding or partial integrin activation. The epitope recognized by HUTS-21 has been mapped to the hybrid domain of β 1 integrin (Luque et al., 1996) . This mAb was added to Jurkat E6.1 cells in the presence of VCAM-1 (2 μg·mL À1 ), and fluorescence was assayed using flow cytometry. As expected, HUTS-21 binds to β 1 integrin and exhibits increased Jurkat cell-associated fluorescence compared to the cells exposed to an isotype control mAb. The binding of α 4 β 1 integrin to its endogenous ligand VCAM-1 induces a conformational rearrangement in the β 1 subunit that exposes the HUTS-21 epitope and increases antibody binding. As shown in Figure 2C , DS-70 (10 À10 
DS-70 inhibits VCAM-1-mediated mast cell and eosinophil degranulation
Integrin α 4 plays a crucial role in allergic reactions because it is expressed on mast cells (Yasuda et al., 1995; Hallgren and Gurish, 2011) and eosinophils (Barthel et al., 2008) . Integrin adhesion molecules are involved in the trafficking of inflammatory cells from the circulation into inflamed tissues (Kourtzelis et al., 2017) and contribute to acute mast cell degranulation following allergen exposure (Hojo et al., 1998) . Consistent with this latter observation, VCAM-1 (2 μg·mL À1 ) caused significant degranulation of the human The results of semiquantitative densitometry analysis of the bands from five independent experiments are shown (mean ± SD); the amount of pERK 1/2 is normalized to that of total ERK 1/2. *P < 0.05, significantly different from vehicle; # P < 0.05, significantly different from VCAM-1. (C) Mean fluorescence intensity (MFI) due to the anti-β1 integrin mAb PE conjugated HUTS-21 plotted against different concentrations of DS-70 added to Jurkat E6.1 cells in the presence of VCAM-1 (5 μg·mL À1 ) was measured. Each point represents the mean ± SD of five independent experiments carried out in triplicate. VCAM-1 administered alone was able to promote epitope exposure and a significant increase of MFI over vehicle-treated cells exposed to PE conjugated HUTS-21 alone (MFI values were 130 ± 3 vs. 80 ± 4; n = 5. P < 0.05, significantly different from VCAM-1 alone. Non-specific binding of an isotype control PE conjugated mAb added to Jurkat E6.1 cells produced an MFI of 38 ± 4 (n = 5) that was subtracted from all samples.
mast cell line HMC 1.1, as assayed by measuring the release of β-hexosaminidase into the cell supernatant. This effect was prevented by exposing the cells to a mAb that binds to the α 4 β 1 integrin expressed on the cell surface. Pretreatment with DS-70 (10 À10 -10 À4 M) 60 min prior to VCAM-1 administration caused a concentration-dependent inhibition of VCAM-1-induced mast cell degranulation ( Figure 3A) . VCAM-1 may interact with several cytokines to promote eosinophil recruitment during the initiation phase of inflammation, and the functional activation of eosinophils is characterized by degranulation (Nagata et al., 1998) . IL-5 plays a fundamental role in eosinophil differentiation in the bone marrow, as well as recruitment and activation at sites of allergic inflammation (Broughton et al., 2015) . Based on this premise, we found that VCAM-1 or IL-5 promote a significant EoL-1 degranulation by measuring the release of eosinophil peroxidase in cell culture medium. IL-5-induced release of eosinophil peroxidase was significantly increased following a 4 h incubation in VCAM-1-coated wells; this effect was blocked by a mAb that binds to α 4 integrin. DS-70 (10 À10 -10 À4 M) prevents the IL-5-induced release of eosinophil peroxidase from cells maintained in VCAM-1-coated wells in a concentration-related manner whereas, when added to control cells, DS-70 was not effective ( Figure 3B ).
DS-70 does not promote cell apoptosis and necrosis
We analysed the capacity of DS-70 to induce apoptosis and necrosis in the three cell lines used in this study: Jurkat E6.1, HMC 1.1 and EoL-1. Cells were treated with DS-70 (10 À4 M) for 6 h, and cell apoptosis and/or necrosis were assessed by flow cytometry; we measured annexin V-PE fluorescence using 7-AAD-induced apoptotic cells as a positive control. As shown in Figure S6 , DS-70 did not cause any significant apoptotic cell death in the three cell lines investigated. Compared with the control, the number of live cells did not decrease, and the percentages of early apoptotic cells, late apoptotic/secondary necrotic or damaged cells did not change in the presence of DS-70.
DS-70 eye drops reduce allergic reactions in guinea pigs and conjunctival α 4 integrin
Guinea pigs were actively immunized via i.p. administration of ovalbumin and challenged with ovalbumin instilled into the conjunctival sac 21 days later. One hour after challenge, during the early phase reaction, clinical observations revealed typical early phase symptoms of allergic conjunctivitis, such as tearing and discharge, conjunctival redness and chemosis. The mean clinical score reached the maximum 2 h after allergen challenge and thereafter showed a progressive decrease. At 24 h after challenge, the conjunctiva did not present any relevant clinical symptom . The administration of DS-70 eye drops (0.01, 0.05 and 0.1%, w/v) in the conjunctival sac of both eyes (30 μL per eye) of ovalbumin-sensitized guinea pigs 30 and 10 min before topical ovalbumin challenge reduced inflammatory signs observed in the early and late phases of conjunctival allergy DS-70 as an allergic conjunctivitis treatment in a dose-dependent manner. The 0.1% dose was the most effective. The topical administration of DS-70 eye drops (0.1%; administered twice 20 min apart) in control guinea pigs sensitized with saline did not cause any significant sign of discomfort or any conjunctival inflammatory symptoms (Figure 4) . A selective and sensitive LM-MS/MS method was developed for the analysis of DS-70 and the internal standard levocabastine hydrochloride in the guinea pig conjunctiva. Both the analyte and the internal standard had similar molecular weight and ClogP values. Adopting this procedure, DS-70 administered to the conjunctival fornix (30 μL of 0.1 g·100 mL À1 ) twice, 30 min apart, was detected in the conjunctiva 1 h after the first treatment (7780 ± 1000 ng·g À1 wet tissue). Interestingly, conjunctival DS-70 was also detected at lower levels, 6 h after the first treatment (3450 ± 800 ng·g À1 wet tissue). The effects of DS-70 on allergic ocular conjunctivitis were compared to those induced by a reference drug dexamethasone ( Figure S7 ). Dexamethasone eye drops (0.1%, w/v) administered to a separate group of guinea pigs sensitized and challenged with ovalbumin as described above produced a reduction of allergic conjunctivitis, superimposable on the effect elicited by DS-70 (0.1%) ( Figure S7 ).
Figure 4
Effects of DS-70 on conjunctival symptoms induced by ovalbumin (OVA) in guinea pigs. Guinea pigs sensitized and challenged with ovalbumin and treated with the vehicle used to dissolve DS-70 (vehicle + OVA) responded with an increase in clinical score index. Administration of DS-70 significantly counteracts, in a dose-related manner, pathological signs and improves eye appearance. Data are presented as scatter plot and refer to the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10). *P < 0.05, significantly different from saline + vehicle; # P < 0.05, significantly different from vehicle + OVA.
These data are in agreement with our previous paper (Baiula et al., 2011) . Guinea pigs were killed 24 h later, and tissues were analysed histologically. Numerous mast cells infiltrating the lamina propria and stroma of the conjunctiva were observed, and most had degranulated in guinea pigs sensitized and challenged with ovalbumin. It was possible to recognize both metachromatic and degranulated mast cells with May-Grünwald-Giemsa staining ( Figure S8A ). In contrast to vehicle-treated guinea pigs, DS-70 caused a dose-dependent reduction in the number of infiltrating degranulated mast cells, and the majority were granulated mast cells (Figures 5A  and S8A) .
Similarly, eosinophil infiltration and eosinophil peroxidase activity, which are used as an index of the conjunctival infiltration of eosinophils (Qasem et al., 2008) , were increased in specimens of tarsal conjunctiva obtained from guinea pigs killed 24 h after antigen sensitization and challenge, whereas a notable, dose-dependent reduction in both parameters was observed in DS-70-treated guinea pigs ( Figure 5B,C) .
Exposure of ovalbumin-sensitized guinea pigs to the topical challenge of ovalbumin instilled into the conjunctival sac induced a significant increase in α 4 integrin levels in sections of tarsal conjunctiva after 24 h, as measured by immunohistochemistry. This increase may be a consequence of the elevated infiltration of leukocytes, such as eosinophils expressing this integrin in the conjunctiva, including mast cells. Interestingly, DS-70 significantly reduced α 4 integrin expression in conjunctival specimens obtained from treated guinea pigs in a dose-dependent manner ( Figure 6 ).
Immunofluorescence analysis carried out on sections obtained from tarsal conjunctiva specimens of guinea pigs sensitized and challenged with ovalbumin showed a double staining for tryptase, as marker of mast cells (Hojo et al., 1998) and α 4 integrin. Moreover, the double staining of MBP, a marker of eosinophils (Nagata et al., 1998) , and α 4 integrin showed the presence of both proteins in specimens of tarsal conjunctiva ( Figure S9 ). Numerous cells positive for double staining were observed, confirming that α 4 integrin is expressed on both mast cells and eosinophils localized in conjunctival specimens ( Figure S9 ).
DS-70 eye drops reduce conjunctival levels of chemokine and cytokine mRNAs and protein content of CCL5 and CCL11 in ovalbumin-treated guinea pigs
Ovalbumin challenge in actively immunized guinea pigs induced a significant elevation of the levels of mRNAs for IL-8, IL-1β, CCL5 and CCL11, and of protein levels of CCL5 and CCL11, in tarsal conjunctival specimens after 24 h. Pretreatment with DS-70 prior to ovalbumin challenge effectively and dose-dependently reduced the conjunctival levels of the cytokine and chemokine mRNAs (Figure 7 ) as well as CCL5 and CCL11 protein levels ( Figure 8 ).
Discussion
In our continuing investigations of small molecules possessing the pharmacological profile of integrin antagonists, we designed and synthesized two novel peptidomimetics. DS-70 possesses a β-amino acid that contributes to increased serum stability compared to the reference α 4 β 1 integrin antagonist BIO1211 (Lin et al., 1999) . Furthermore, this component contributed to the stable conformation of the overall structure.
DS-70 prevents the adhesion of Jurkat E6.1 cells, an immortalized human T lymphocyte line, EoL-1 cells, a human Figure 5 DS-70 prevents, in a dose-dependent manner, conjunctival infiltration and degranulation of mast cells and eosinophils. (A) The number of degranulated mast cells was evaluated in photographs taken of 10 random fields of 10 different conjunctival sections (see photomicrographs of tarsal conjunctiva stained with May-Grünwald-Giemsa shown in Figure S8A ) and reported as percentage of degranulated mast cells (calculated with the following formula: DMC/MC × 100). (B) Effects of DS-70 eye drops on conjunctival eosinophil infiltration 24 h after topical challenge with ovalbumin. Substantial eosinophil infiltration was observed in guinea pigs sensitized and topically challenged with ovalbumin. In guinea pigs sensitized with ovalbumin, treated with DS-70 eye drops and challenged with ovalbumin, there was a lower, dose-related, eosinophil infiltration than in conjunctiva of guinea pigs treated with ovalbumin alone. The number of eosinophils was determined in photographs taken of 10 random fields of 10 different sections (Luna's staining; see Figure S8B ). (C) Effects of DS-70 eye drops on conjunctival eosinophil peroxidase levels 24 h after topical challenge with ovalbumin. Data refer to the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10). *P < 0.05, significantly different from saline + vehicle; # P < 0.05, significantly different from vehicle + OVA. In guinea pigs sensitized and challenged with ovalbumin and treated with the vehicle used to dissolve DS-70 (vehicle + OVA), IHC score is markedly increased, and DS-70 at the concentration 0.1% maximized the reduction that can be seen already observed at 0.05%. Data are presented as the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10). Black bars = 50 μm. *P < 0.05, significantly different from saline + vehicle; # P < 0.05, significantly different from vehicle + OVA.
eosinophilic leukaemia cell line, and HMC 1.1 cells, a human mast cell line, all of which express integrin α 4 β 1 , to VCAM-1 and FN. Although DS-70 is eightfold less potent in preventing the adhesion of RPMI 8866 cells that express α 4 β 7 (Erle et al., 1994) to MAdCAM-1 than cells that express α 4 β 1 integrin, DS-70 still prevents adhesion in the nanomolar range. Thus, this novel compound may be considered a dual antagonist of α 4 β 1 /α 4 β 7 integrins. We further characterized DS-70 as an effective antagonist of α 4 integrin by showing that it antagonized VCAM-1-mediated phosphorylation of ERK 1/2 in Jurkat E6.1 cells and VCAM-1-mediated degranulation of HMC 1.1 mast cells and EoL-1 cells.
Consistent with other studies (Karanam et al., 2007) , the reference α 4 β 1 integrin antagonist BIO1211 is metabolically unstable when added to mouse serum in vitro (t 1/2 = 2.1 h), whereas only 21% of DS-70 was degraded under the same experimental conditions. These data further confirm the potential for DS-70 to be developed as drug for administration in vivo. Following administration of DS-70 in the guinea pig conjunctival fornix, it was detected in the conjunctiva. Higher levels were measured 1 h later, but it was still present 6 h after treatment. These data provide more evidence for the antiallergic effects that this agent promotes at conjunctival level.
Figure 7
DS-70 eye drops (0.1% suspension) induced a significant down-regulation of IL-8, IL-1β, CCL5 and CCL11 transcripts in conjunctiva. Relative fold changes in mRNA levels were calculated using the ΔΔC t method as described in the Methods. Ovalbumin challenged animals (vehicle + OVA) behave as positive control; DS-70 0.05% and DS-70 0.1% reduce this increase. Values are the mean ± SD (five animals per group were included, and both eyes were evaluated; n = 10). *P < 0.05, significantly different from saline + vehicle; # P < 0.05, significantly different from vehicle + OVA.
Using the mAb PE conjugated HUTS-21 that recognizes a ligand-induced binding site epitope of β 1 integrin expressed with the α 4 subunit (Luque et al., 1996) , DS-70 concentration-dependently reduced the exposure of HUTS-21 epitope, as measured by mAb binding in the presence of the endogenous α 4 β 1 agonist VCAM-1. Finally, in a model of allergic conjunctivitis, DS-70 eye drops dose-dependently antagonized the clinical symptoms of conjunctival allergy and the conjunctival expression of α 4 integrin by reducing infiltration of leukocytes, such as eosinophils expressing this integrin in the conjunctiva, including mast cells.
The α 4 β 1 integrin/VCAM-1 pathway seems to be crucial for the firm adhesion and transmigration of mast cells (Parmley et al., 2007) and eosinophils (Nagata et al., 1998) into the conjunctiva through vascular endothelial cells. The inhibition of conjunctival eosinophil infiltration by an integrin mAb has been reported in a guinea pig model of allergic conjunctivitis (Ebihara et al., 1999) . Furthermore, treatment with anti-α 4 integrin and anti-VCAM-1 antibodies significantly suppressed the conjunctival eosinophil infiltration induced in mice following active immunization with ragweed or adoptive transfer of ragweed-primed splenocytes (Fukushima et al., 2006) . As shown by Higashimoto et al. (1999) , the adhesion of eosinophils to FN is mediated by α 4 β 1 integrin, potentially contributing to the increased cell adhesion to the extracellular matrix and conjunctival eosinophil accumulation. Tissue sections from guinea pigs treated with saline (saline + vehicle) and DS-70 alone (saline + DS-70 0.1%) were used as a negative control. Scale bar, 50 μm. Data are presented as mean ± SD (fie animals per group were included, and both eyes were evaluated; n = 10). *P < 0.05, significantly different from saline + vehicle; # P < 0.05, significantly different from vehicle + OVA.
These in vitro data may help to explain the reduction in the expression of α 4 integrin observed in the conjunctiva of ovalbumin-sensitized guinea pigs treated with DS-70. In fact, this effect might be a consequence of the DS-70-mediated reduction in the recruitment and migration of mast cells and eosinophils to the site of allergic inflammation, rather than of the down-regulation of α 4 β 1 induced by DS-70. This hypothesis is further supported by the findings that integrins increase their affinity or avidity for endothelial-expressed adhesion molecules upon exposure to chemokines and undergo conformational changes upon ligand binding in addition to changes in their expression on the leukocyte surface (Hyduk and Cybulsky, 2009 ).
We ascertained the positive effect of DS-70 eye drops on inflammatory changes induced by allergen-specific conjunctival challenge. This novel molecule, topically administered prior to ovalbumin challenge, effectively and dosedependently reduced the conjunctival levels of the cytokines IL-1β and IL-8 and of the chemokines CCL5 and CCL11 at both mRNA and protein levels. Histamine and eicosanoids are responsible for the typical early phase response (Katelaris, 2003) . However, mast cells also contribute to the synthesis and release of cytokines, chemokines and growth factors, triggering a cascade of inflammatory events on the surface of epithelial and endothelial cells that leads to the late phase reaction, along with the recruitment of eosinophils and neutrophils (Abelson et al., 2015) . These latter cytokines participate in the production of chemokines, including CCL5 and CCL11, from conjunctival cells. The chemokine gradient regulates the trafficking of neutrophils, eosinophils and lymphocytes to the conjunctiva occurring during the late phase. CCL5 and CCL11 are included among major eosinophil chemoattractants. Furthermore, they are produced by eosinophils and are released during allergic responses. Mast cells express receptors for CCL5 and CCL11 and other chemokines that induce mast cell activation contributing to ongoing cellular infiltration and conjunctival hyperresponsiveness of the late phase (Komi et al., 2018) . Inflammatory cytokines may also enhance the expression of E-selectin, ICAM-1 and VCAM-1 on vascular endothelial cells and initiate the rolling and adhesion of immune cells (Bacon et al., 1998) .
By reducing mast cell degranulation, DS-70 eye drops may decrease the early phase response in ovalbumin-challenged guinea pigs and contribute to the conjunctival eosinophil infiltration in the late phase response. Consequently, conjunctival levels of cytokine and chemokine mRNAs are decreased (Pacharn and Vichyanond, 2013) . These effects are further supported by α 4 integrin localized on conjunctival mast cells and eosinophils. Conjunctival epithelial cells do not express α 4 β 1 integrin (Fujihara et al., 1997) , and its expression in the conjunctiva may be derived from infiltrated inflammatory cells and promoted by different mechanisms.
According to serum stability studies and detection of topically applied DS-70 in the conjunctiva, it may be absorbed by conjunctival blood vessels and may persist at an adequate conjunctival concentration for up to 6-8 h, a sufficient period to interfere with mast cell activation and eosinophil migration to the ocular surface. We propose DS-70 as a novel α 4 integrin antagonist capable of relieving symptoms of allergic conjunctivitis in an appropriate animal model, and some of the targets of this drug include the conjunctival infiltration of mast cells and eosinophils and the reduction of α 4 integrin expression.
Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of the article.
https://doi.org/10.1111/bph.14458( Figure S1 Relevant steps of the synthesis designed for DS-70 (A) and DS-23 (B) compounds, as described in the Methods. Figure S2 Guinea pigs sensitized and challenged with ovalbumin and treated with the vehicle used to dissolve DS-70 (vehicle +OVA) were responsive to the treatment with the consequent increase in clinical score index. Administration of Dex significantly counteracts pathological signs and improves eye appearance. In control guinea pigs sensitized with saline and treated with the vehicle (saline+vehicle) or Dex (saline + Dex 0.1%) no signs of allergic conjunctivitis were observed. Data are presented as scatter plot and refer to the mean ± SD (5 animals per group were included and both eyes were evaluated; n = 10). *P < 0.05 vs. saline + vehicle; # P < 0.05 vs. vehicle + OVA. 
